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Abstract: The open-label, phase II clinical trial of antituberculosis therapy (ATT) with or 
without oral immunomodulator Dzherelo (Immunoxel) was conducted in TB/HIV coinfected, 
antiretroviral therapy naïve patients to evaluate the effect on CD4 T-lymphocyte counts and viral 
load. The arm A (n = 20) received isoniazid (H); rimfapicin (R); pyrazinamide (Z); streptomycin 
(S); and ethambutol (E), and arm B (n = 20) received 50 drops of Dzherelo twice per day in 
addition to HRZSE. After 2 months in 90% of Dzherelo patients the population of absolute CD4 
T-cells expanded by an average of 71.2% (from 174 to 283 cells/μl; P = 0.00003), but declined 
in ATT-alone patients (182 to 174; P = 0.34). The ratio between CD4/CD8 cells deteriorated 
in 80% of individuals in arm A (1.213  0.943; P = 0.002), but improved in the same propor-
tion of patients in arm B (1.244  1.536; P = 0.007). The number of total CD3+ lymphocytes 
rose from 728 to 921 cells in arm B (P = 0.025) whereas it fell from 650 to 585 cells in arm A 
(P = 0.25). The viral load, as measured by plasma RNA-PCR, decreased in 70% of Dzherelo 
recipients (2.174  1.558 copies/ml; P = 0.002), but increased in 70% of HRZSE only receivers 
(1.907  2.076 copies/ml; P = 0.03). Dzherelo has a favorable effect on the immune status and 
viral burden in TB/HIV patients when given as an immunomodulating adjunct to ATT.
Keywords: dual infection, herbal, immunotherapy, MDR-TB, multi-drug resistant, Mycobac-
terium tuberculosis, phytotherapy, Ukraine, XDR-TB
Introduction
In developing countries, tuberculosis (TB) coinfection is common among human immu-
nodeﬁ  ciency virus (HIV)-positive individuals with probability of death 2- to 3-fold 
higher than among acquired immunodeﬁ  ciency syndrome (AIDS) patients without 
active TB (Gupta et al 2007). The World Health Organization estimates that a person 
with both HIV and TB infection is thirty times more likely to become ill with TB than a 
person with Mycobacterium tuberculosis infection alone (Reid et al 2006). Ukraine has 
the highest rate of TB/HIV coinfection in Eastern Europe (van der Werf et al 2006). It 
is recognized that the effectiveness of TB therapy is signiﬁ  cantly lower among patients 
with HIV/AIDS. The occurrence of mortality and relapse are consistently higher even 
when TB/HIV patients are treated with antituberculosis therapy (ATT) under directly 
observed therapy (DOT) (Khauadamova et al 2001). Drug resistance accompanied by 
HIV-associated immunodeﬁ  ciency is the main cause of treatment failure. The recent 
survey of Nikolayevskyy and colleagues (2007) had shown that in Southern Ukraine 
the multi-drug resistance (MDR) rates were signiﬁ  cantly higher among former prison 
inmates compared with nonprisoners (54.8% vs. 27.3%).
The oral immunomodulator Dzherelo has been successfully used in Ukraine for 
the management of TB and HIV infections, including patients with dual infection. 
Published studies by us and others have demonstrated that Dzherelo can signiﬁ  cantly Drug Design, Development and Therapy 2008:2 88
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shorten the duration of treatment and helps to achieve 
higher response rate even in those who are HIV coinfected, 
have MDR or extensively-drug resistant (XDR) forms of 
TB (Chkhetiany et al 2007; Prihoda et al 2007; Nikolaeva 
et al 2008). Dzherelo has also been found to decrease the 
hepatotoxicity resulting from TB chemotherapy (Zaitzeva 
2006). Dzherelo was approved in 1997 by the Ministry of 
Health of Ukraine as an immunomodulating supplement. In 
1999, Dzherelo was recommended as an immune adjunct to 
the conventional therapy of pulmonary tuberculosis (Melnik 
et al 1999). Dzherelo contains aqueous-alcohol extract from 
various medicinal plants. So far, Dzherelo has been used by 
over 150,000 individuals for various indications including 
chronic bacterial and viral infections such as TB and HIV, 
autoimmune diseases, and malignancy.
Several studies have shown that, similarly to HIV, 
the immune control of M. tuberculosis is dependent from 
CD4+ T-lymphocytes (Serbina et al 2001; Morris et al 
2003; Manas et al 2004; Kalou et al 2005). The M. tuber-
culosis and HIV infections are associated with pronounced 
deterioration of the immune system as evidenced by higher 
depletion rate of helper CD4+ cells and enhanced HIV 
replication. The immunotherapeutic approaches toward 
TB began receiving more attention recently (Tomioka 
2004; Kaufmann 2006; Achkar et al 2007). There are 
many types of immune modulators that have been used 
clinically for viral infections, but for TB the choice of 
immune interventions is limited (Ershov 2003). Our 
study was aimed at evaluating the effect of Dzherelo on 
T-lymphocyte populations and viral load among TB/HIV 
patients in comparison with control population, which 
received the ATT only.
Materials and methods
Patients
Male patients, aged 19–42 years, have been randomized into 
arms A and B, each consisting of 20 patients. The majority 
of patients in our study were correctional facility inmates in 
advanced clinical stage III of HIV-1 infection with average 
baseline CD4+ T-cell counts below 200 cells/microliter 
(cells/μl). The diagnosis of HIV infection was established 
by standard ELISA test and further conﬁ  rmed by Western 
blot. Active pulmonary tuberculosis was certiﬁ  ed by a medi-
cal history and clinical ﬁ  ndings compatible with pulmonary 
tuberculosis, a chest X-ray showing lung involvement, and 
positive sputum smear for acid-fast bacilli or the culture of 
M. tuberculosis. The conduct of the trial was approved by 
the State Department of the Penitentiary of Kharkov region, 
Ukraine. The participation in this trial was voluntary and 
patients were eligible to enroll only after signing the writ-
ten consent.
Treatment regimens
None of the patients received antiretroviral therapy prior 
to and during 2-months of follow-up. All patients received 
standard antituberculosis therapy administered under DOT 
schedule which consisted of once daily dose of isoniazid (H) 
300 mg; rimfapicin (R) 600 mg; pyrazinamide (Z) 2,000 mg; 
streptomycin (S) 1,000 mg; and ethambutol (E) 1,200 mg. 
The arm B received, in addition to HRZSE, twice per day 
dose of Dzherelo which was given as 50 drops diluted in a 
half-glass of water. Dzherelo contains concentrated aqueous-
alcohol extract from medicinal plants such as Aloe (Aloe 
arborescens), Common knotgrass (Polygonum aviculare), 
Yarrow (Achillea millefolium), Purple coneﬂ  ower (Echina-
cea purpurea), St. John’s Wort (Hypericum perforatum), 
Centaury (Centaurium erythraea), Snowball tree berries 
(Viburnum opulus), Nettle (Urtica dioica), Dandelion 
(Taraxacum ofﬁ  cinale), Sweet-sedge (Acorus calamus), 
Oregano (Oreganum majorana), Marigold (Calendula 
ofﬁ  cinalis), Seabuckthorn berries (Hippophae rhamnoides), 
Elecampane (Inula helenium), Tormentil (Potentilla erecta), 
Greater plantain (Plantago major), Wormwood (Artemisia sp.), 
Siberian golden root (Rhodiola rosea), Cudweed (Gnapha-
lium uliginosum), Licorice (Glycyrrhiza glabra), Fennel 
(Foeniculum vulgare), Chaga (Inonotus obliquus), Thyme 
(Thymus vulgaris), Three-lobe Beggarticks (Bidens tripar-
tite), Sage (Salvia ofﬁ  cinalis), Dog rose (Rosa canina), and 
Juniper berries (Juniperus communis). The over-the-counter 
phytoconcentrate Dzherelo was generously supplied by 
Ekomed company (Kiev, Ukraine).
Immunophenotyping of lymphocyte 
subsets
The peripheral blood of patients with TB/HIV was analyzed 
with Clonospectr panel of monoclonal antibodies against 
surface antigens of T-lymphocytes (MedBioSpectr, Moscow, 
Russia). The absolute and relative (%) values of total CD3+ 
lymphocytes, helper T lymphocytes (CD3+CD4+) and 
cytotoxic T lymphocytes (CD3+CD8+) were assessed in a 
blinded fashion by ﬂ  uorescent microscopy at baseline and 
after 1 and 2 months on the therapy. In addition the changes 
in the ratio between CD4 and CD8 cells were evaluated as 
a part of assessment of the immune status of patients. The 
samples of the blood from 19 healthy blood donors were 
analyzed as a reference for normal values.Drug Design, Development and Therapy 2008:2 89
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PCR analysis
Stored frozen samples of plasma were processed in bulk 
with commercially available PCR kit (AmpliSense HIV-1, 
Central Research Institute of Epidemiology, Moscow, Russia) 
designed for quantitative analysis of HIV-RNA copies. Tests 
were carried out at baseline and after two months of the 
therapy.
Statistical analysis
The obtained results were analyzed with the aid of statistical 
software STATMOST (Datamost, South Sandy, UT). The 
baseline cell numbers relative to 1st and 2nd months post-
therapy were evaluated by paired Student t-test. Unpaired 
t-test was used to compare data from TB/HIV patients to 
normal blood donors. The nonparametric values of viral load 
were evaluated by Wilcoxon signed-rank test. Spearman 
rank-order test was used for correlation analysis, which was 
carried out on absolute and relative numbers of T-cells and 
PCR results. The correlation analysis was also conducted 
on differential values of these parameters, ie, differences 
between baseline and 2-month results. All statistical cal-
culations were per intent-to-treat basis or the total number 
of patients without subgrouping them into responders and 
nonresponders. The probability values were considered as 
signiﬁ  cant at P  0.05.
Results
After one month of therapy there was a clear distinction in 
measured T-cell counts between recipients of ATT-alone 
and those who received ATT with Dzherelo. This disparity 
became even more evident at the end of the second month 
of therapy (Figure 1). The changes in viral load among 
TB/HIV patients of both groups have also reached statisti-
cal signiﬁ  cance even though none of the patients have ever 
received the antiretroviral therapy (Table 1). These ﬁ  ndings 
are described in detail as follows.
CD3+ total T-lymphocytes
After one month on ATT-alone arm, the absolute and per-
cent (%) values of total CD3+ lymphocytes per microliter 
of blood have not changed appreciably, ie, 650 (36.8%) vs. 
634 (37.2%); P = 0.38 (P = 0.23), as analyzed by paired Stu-
dent t-test. However, in the HRZSE group, which received 
Dzherelo, there was a signiﬁ  cant difference in total CD3+ 
values as early as one month post-therapy, ie, 728 (37.5%) 
vs. 902 (40.4%); P = 0.015 (P = 0.04). After 2 months, the 
number of total CD3+ lymphocytes increased further to 921 
in arm B (P = 0.025) whereas in the control arm it decreased 
to 585 cells (P = 0.25). The difference in treatment out-
comes between two groups, ie, 921 vs. 585 was signiﬁ  cant 
(P = 0.004), while baseline values were not statistically 
Figure 1 Changes in T-lymphocyte relative and absolute numbers at 2 months post-therapy as expressed in percentage values relative to their respective baseline levels.
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different (P = 0.15). Compared with baseline there was a 
26% increase and 11.2% decrease in absolute number of total 
lymphocytes in arms B and A respectively (Figure 1). In arm 
B, 15 out of 20 (80%) patients were responders displaying 
the increase in absolute CD3 lymphocytes, while in arm A, 
less than half of patients (45%) had a positive response.
CD4+ T-lymphocytes
No signiﬁ  cant changes were seen after one month in ATT-
alone arm, ie, from 182 (24.2%) to 203 (24.5%) cells/μl; 
P = 0.063 (P = 0.28), whereas in the Dzherelo arm, the 
number of helper cells have risen signiﬁ  cantly from 174 
(23.3%) to 257 (27.3%) cells; P = 0.00003 (P = 0.0004). At 
the end of the second month, CD4 lymphocytes in arm B 
have risen further to 283 (31%) P = 0.0000004. However, the 
changes in arm A were insigniﬁ  cant 174 (25.3%) P = 0.13. 
When study completion results of Dzherelo recipients were 
compared in terms of accrual of CD4+ lymphocytes with the 
entry levels, there was a highly signiﬁ  cant increase of 34% 
and 71% in relative and absolute values. In arm A, relative 
and absolute CD4 cell numbers fell by 4.5% and 5.5%, 
respectively. The absolute and relative CD4 numbers were 
indistinguishable at baseline with P = 0.4 (P = 0.2), but at 
study conclusion the differences became highly signiﬁ  cant 
with P = 0.001 and P = 0.003 for absolute and relative val-
ues, respectively. Out of 20 patients on Dzherelo 18 (90%) 
had seen their T-cells rise, while among those who received 
HRZSE-alone only 40% of patients had shown the increase 
in absolute CD4 lymphocytes (Figure 1).
CD8+ T-lymphocytes
After one month in the HRZSE-alone group, CD8+ cells 
increased in a signiﬁ  cant manner from 159 (21.7%) to 199 
(24.3%); P = 0.01 (P = 0.02), while in the Dzherelo group, 
the changes were insigniﬁ  cant, ie, from 159 (20.8%) to 190.2 
(19.8%); P = 0.21 (P = 0.05). At the end of the second month, 
the CTL population in the ATT-alone group was still above 
baseline, ie, 180 cells (27.7%), an accrual that was statistically 
signiﬁ  cant in percent terms (P = 0.000009), but not signiﬁ  -
cant when calculated in absolute numbers (P = 0.17). On the 
contrary, in the second month, numbers of CD8 cells among 
Dzherelo recipients had not increased in any signiﬁ  cant man-
ner, from 159 (20.8%) to 183 (20.7%), with P values being 
0.13 and 0.47 for absolute and percent ﬁ  gures, respectively 
(Figure 1). The absolute and relative CD8 numbers were 
almost identical between two arms at baseline 159 (21.7%) 
vs. 159 (20.8%) at P = 0.5 (P = 0.3), but at study conclusion 
they reached P = 0.4 and P = 0.00002 for absolute and rela-
tive values, respectively. In the HRZSE arm, 70% and 85% 
of patients had shown an increase in absolute and relative 
numbers of CD8 lymphocytes, while in the Dzherelo group, 
65% and 50% of patients had a similar response.
CD4/CD8 ratio
The differential changes in CD4 and CD8 lymphocyte 
numbers had affected the CD4/CD8 ratio in patients on the 
HRZSE-alone regimen as early as one month after treatment 
initiation. Their ratio had declined from 1.213 baseline value 
to 1.06 (P = 0.009). In contrast, the CD4/CD8 ratio among 
Dzherelo recipients increased from 1.244 to 1.416, which 
was, however, slightly above the cut-off value (P = 0.06). 
The disparity between CD4 and CD8 lymphocytes had 
progressed even further by the end of the second month. 
Among HRZSE-alone patients the ratio had declined to 0.943 
(P = 0.002), while in the Dzherelo group the ratio had risen 
to a level that is commonly considered to be as a normal, ie, 
1.536 (P = 0.007). This ratio was statistically indistinguish-
able from the ratio of normal blood donors, ie, 1.54 vs. 1.76 
Table 1 Effect of 2-month HRZSE therapy without or with Dzherelo on HIV-RNA plasma levels
Arm A
TB/HIV patients on HRZSE-alone (N = 20)
Arm B
TB/HIV patients on HRZSE + Dzherelo (N = 20)
HIV-RNA copies/ml 
at baseline
HIV-RNA copies/ml 
at 2nd month
Difference com-
pared with baseline
HIV-RNA copies/ml 
at baseline
HIV-RNA copies/ml 
at 2nd month
Difference com-
pared with baseline
Mean ± SD =
1907 ± 5400
Mean ± SD =
2076 ± 5602
Mean ± SD =
+170 ± 298
Mean ± SD =
2174 ± 6353
Mean ± SD =
1558 ± 4725
Mean ± SD =
−616 ± 1651
Geometric
mean = 479
Geometric
mean = 592
Geometric
mean = 122
Geometric
mean = 775
Geometric
mean = 540
Geometric
mean = 253
Median = 343 Median = 403 Median = +86 Median = 699 Median = 470 Median = −258
Wilcoxon signed rank 
test; P = 0.03
Wilcoxon signed rank 
test; P = 0.002
Abbreviations: H, Isoniazid; R, Rifampicin; Z, Pyrazinamide; S, Streptomycin; E, Ethambutol.Drug Design, Development and Therapy 2008:2 91
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(P = 0.09). The proportion of patients who experienced 
increase in their CD4/CD8 ratio was 80% and 20% for arms 
B and A, respectively.
Lymphocyte subsets in normal 
blood donors
Samples of the peripheral blood of 19 healthy individuals 
were analyzed to obtain the normal distribution values of 
lymphocyte subsets. The average number of absolute and 
relative (%) CD3 lymphocytes were 1,370 ± 169 cells/μl 
(52.9 ± 6.8). The values of CD4 and CD8 lymphocytes were 
622 ± 89 (35.9 ± 4.3) and 349 ± 42 (19.9 ± 2.1) respectively, 
with ratio being 1.76 ± 0.19. The absolute numbers of CD3 
and CD8 cells were approximately two-fold and CD4 cells 
three-fold higher than in patients with TB/HIV.
Viral load
The viral load, as measured by plasma RNA-PCR at baseline 
and at the end of the second month, increased in the ATT 
group (1907 to 2076 copies/ml; P = 0.025, by Wilcoxon 
signed rank test), but decreased in the Dzherelo group (2174 
to 1558 copies; P = 0.002). About two-thirds of the patients 
(14/20) on HRZSE-alone had shown the increase in viral load, 
while the same proportion of patients on Dzherelo (70%) had 
a reduction in their number of viral copies (Table 1).
Correlation of viral load with T-cells
The Spearman rank-order analysis has revealed that at study 
conclusion the differential accrual in HIV copies in arm A 
patients seem to be inversely dependent on differential of 
absolute CD4 numbers (r = −0.4124; P = 0.07) but directly 
correlated with relative CD8 counts at two months (r = 0.42; 
P = 0.07). However, the corresponding correlation values in 
Dzherelo recipients were r = −0.01 (P = 0.96) and r = −0.03 
(P = 0.91) for CD4 and CD8 cells, respectively. The only 
signiﬁ  cant correlation found in the Dzherelo arm was an 
inverse relation between differentials of relative CD8 counts 
and viral load (r = −0.46; P = 0.04). The viral load was 
inversely dependent from CD4/CD8 ratio in arm A (r = −0.49; 
P = 0.03), but not in the Dzherelo arm (r = 0.24; P = 0.3). No 
correlation was found between relative and absolute CD3 
cell numbers and HIV RNA levels in arm A, but in arm B 
higher differential counts were signiﬁ  cantly correlated with 
lower viral load (r = −0.49; P = 0.03).
Discussion
Our results indicate that when Dzherelo is added to ATT, 
it can produce a signiﬁ  cant increase in CD3+ and CD4+ 
lymphocytes, and a better CD4/CD8 ratio, but no signiﬁ  cant 
change in CD8-bearing lymphocytes. Furthermore, Dzherelo 
produces statistically signiﬁ  cant lower viral load; an effect 
that we have shown in HIV-infected individuals without 
concomitant TB (Nikolaeva et al 2008).
Our 2-month DOT study conducted in a population con-
sisting mostly of incarcerated individuals reveals that when 
Dzherelo is added to ATT the absolute and relative numbers 
of CD4+ T-cells increase by 71% and 34%, respectively. 
Thus, in our hands Dzherelo produced the same outcome as 
reported earlier (Chkhetiany et al 2007; Prihoda et al 2007; 
Nikolaeva et al 2008). For example, AIDS patients who 
received Dzherelo with or without standard antiretroviral 
therapy gained between 38%–93.5% more CD4 lympho-
cytes (Chkhetiany et al 2007; Nikolaeva et al 2008). It is 
well established that elevated CD3 and CD4 counts and 
higher CD4/CD8 ratio are associated with better prognosis in 
patients with HIV as well as TB (Serbina et al 2001; Morris 
et al 2003; Manas et al 2004; Kalou et al 2005). Dzherelo 
appears to normalize the lymphocyte homeostasis since at the 
end of study the CD4/CD8 ratio of treated patients became 
indiscernible from the ratio of normal healthy individuals, ie, 
1.54 vs. 1.76 (P = 0.09). Thus, Dzherelo is likely to inﬂ  uence 
positively the outcome of treatment and disease progression 
in our study population.
Treatment of TB in HIV-infected individuals is a daunt-
ing task when compared with TB in HIV-negative persons 
(Khauadamova et al 2001; Reid et al 2006; Gupta et al 
2007). This task is particularly challenging when one has to 
treat inmate populations, which as a rule have higher preva-
lence of drug-resistant TB and more advanced HIV disease 
(Nikolayevskyy et al 2007). Due to frequent failure rate of TB 
therapy in this particular population of patients the immune 
intervention with Dzherelo has been sought to evaluate its ben-
eﬁ  t. In the prior studies Dzherelo has been shown to increase 
by two- to three-fold the success rate of ATT and shorten 
signiﬁ  cantly the duration of treatment even among those who 
had MDR-TB or XDR-TB (Prihoda et al 2007). It had also 
reduced the toxic side effects of ATT, the hepatotoxicity in 
particular. Elevated liver aminotransferase ALT and AST 
levels caused by ATT have been shown to return to normal 
levels after addition of Dzherelo (Zaitzeva 2003). Furthermore, 
cachexic patients who received Dzherelo were shown to gain 
weight (Chkhetiany et al 2007; Prihoda et al 2007). However, 
these studies have not dealt with the effect of Dzherelo on viral 
load among dually infected TB/HIV patients.
The viral load is a predictor of HIV disease progression, 
its persistent elevation in TB/HIV coinfected patients is Drug Design, Development and Therapy 2008:2 92
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indicative of poor prognosis (Morris et al 2003; Kalou et al 
2005). While there were earlier indications that Dzherelo 
reduces viral burden (Chkhetiany et al 2007; Nikolaeva et al 
2008), our study is the ﬁ  rst to report this phenomenon in 
TB/HIV patients. Despite the fact that the HIV RNA levels 
had decreased by less than a log the difference between 
baseline and outcome levels was highly signiﬁ  cant. 70% 
of patients in arm A experienced the increase in viral load, 
while the same proportion of patients in arm B had reduced 
viral burden. This observation is encouraging since suc-
cessful ATT regimens, some which reported to restore the 
immunity in TB/HIV patients, were not affecting the viral 
load (Newton et al 2000; Morris et al 2003; Kizza et al 2005). 
Thus, our observation is quite unique. Except, perhaps, tha-
lidomide, prednisone, and likopid, we are not aware of any 
other immunity-restoring preparation that would affect both 
the TB and HIV (Bekker et al 2000; Svistunova et al 2002; 
Mayanja-Kizza et al 2005). However, several experimental 
immunotherapeutic regimens were tried with various degrees 
of success in TB patients including for example interferon, 
tumor necrosis factor antagonists, cytokines, thymus-derived 
Russian immunomodulators such as thymalin, thymogen, 
T-activin, and vilosen (Khudzik et al 1998; Wallis 2005).
Many studies have been conducted aimed at identifying 
the immune cells controlling TB and TB/HIV coinfections. 
While there is a consensus that cellular immune responses 
play a critical role in disease progression, much more has 
to be learned in order to understand the relationship. The 
correlation analysis has revealed a certain degree of rela-
tion between viral load and CD4 or CD8 cells in arm A, but 
they were not statistically signiﬁ  cant except CD4/CD8 ratio. 
Dzherelo does not inﬂ  uence directly HIV replication and it 
is likely that the observed effect on viral load is mediated 
via immune cells (Melnik et al 1999).
Surprisingly, in arm B, the viral load was not dependent 
on changes in CD4 cells although signiﬁ  cant inverse correla-
tion was found with CD3 and CD8 cell numbers. However, 
this arm is characterized by a signiﬁ  cant gain in total and CD4 
T-lymphocytes but not changes in CD8-bearing population. 
Thus, we do not know how and which cells are involved in 
Dzherelo-inﬂ  uenced viral control. It is possible that the viral 
replication is regulated by a subpopulation of T lymphocytes 
which cannot be reliably identiﬁ  ed by surface markers we 
have used. The protective immune response also needs to be 
separated from undesired inﬂ  ammatory response (Achkar 
et al 2007). The possibility that CD8 T-cells are involved 
in upregulation instead of suppression of viral replication is 
suggested by correlation analysis in arm A. On the other hand, 
in arm B the inverse relation between differentials of relative 
CD8 counts and viral load suggests the opposite effect. The 
full signiﬁ  cance of elevated CD3, CD4, CD4/CD8, but 
unchanged CD8 cells resulting from Dzherelo administration 
is yet to be understood. It is clear that the understanding of 
the immune mechanism controlling M. tuberculosis may aid 
in design of better vaccines and immunotherapies. Dzherelo 
confers cellular responses suggestive of immunity-restoring 
action, which perhaps explains the higher success rate of the 
therapy when it is combined with ATT.
Currently available chemotherapy for the treatment of 
TB are not perfect, they require multiple anti-TB drugs to 
be taken in combination for long periods of time (Gupta et al 
2007; Reid et al 2006). This can cause side effects, poor drug 
adherence, treatment failure, and the emergence of drug 
resistance with major social and economic consequences, 
especially in low-income countries. It is agreed that novel 
immune-based therapies are urgently needed to complement 
antitubercular drug discovery (Khudzik et al 1998; Tomioka 
2004; Wallis 2005; Kaufmann 2006; Achkar et al 2007). We 
also believe that the immunotherapy is the indispensable 
part of therapeutic strategies against TB (Pylypchuk 2003). 
Many effective immunomodulators are available against 
bacteria, protozoa, fungi and viruses (Ershov 2003). While 
clinically effective their mechanism is not well understood 
in most cases. This drawback should be balanced against 
therapeutic beneﬁ  ts. Some medicinal herbs were shown to 
modulate the immune response to TB (Tomioka 2004), while 
others exerted direct antimycobacterial activity (Newton 
et al 2000). But it is unlikely that Dzherelo is tuberculostatic 
since it does not affect mycobacterial growth in vitro and 
diseases or pathogens etiologically unrelated to M. tuber-
culosis were responsive to the therapy (Melnik et al 1999; 
Pylypchuk 2003).
Our study provides preliminary evidence into the putative 
mechanism of action of Dzherelo, which has been recom-
mended in Ukraine as an immune adjunct to TB therapy. 
Further studies are required to develop better understanding 
of the potential of Dzherelo and to enlarge the arsenal of 
tuberculosis drugs.
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